Physician profile
John Holt
NPI 1477524783
$6,718.28
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $859 · 2021: $1,996 · 2022: $1,786 · 2023: $723 · 2024: $30.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.57 | 2019-2024 | |
| Gilead Sciences, INC. | $932.99 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $792.20 | 2019-2023 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $613.16 | 2019-2023 | Entyvio, Gattex |
| Pfizer INC. | $474.42 | 2019-2023 | |
| Janssen Biotech, INC. | $357.31 | 2019-2023 | Stelara |
| Celgene Corporation | $240.15 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $236.78 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Ferring Pharmaceuticals INC. | $192.12 | 2019-2023 | Cimzia, Rebyota |
| Merck Sharp & Dohme LLC | $181.73 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $162.92 | 2019-2023 | Ocaliva |
| Amgen INC. | $154.79 | 2021-2023 | Avsola, Amjevita |
| Ucb, INC. | $119.84 | 2019-2020 | |
| Braintree Laboratories, INC. | $118.00 | 2020-2022 | |
| Daiichi Sankyo INC. | $100.29 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $88.17 | 2021-2022 | |
| Qol Medical, LLC | $70.62 | 2022-2023 | Sucraid |
| Shire North American Group INC | $34.87 | 2019 | |
| Concordia Pharmaceuticals INC. | $34.83 | 2019 | |
| Fresenius Kabi USA, LLC | $34.41 | 2023 | Idacio |
| Genzyme Corporation | $32.61 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.71 | 2021 | |
| Intra-Sana Laboratories | $19.42 | 2021 | |
| Medtronic, INC. | $19.21 | 2023 | Gi Genius |
| Dova Pharmaceuticals | $16.89 | 2019 | |
| Evoke Pharma, INC. | $16.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.41 | 2019 | |
| Biosense Webster, INC. | $14.89 | 2023 | Carto 3 |
| Ironwood Pharmaceuticals, INC | $14.53 | 2020 | |
| Organon LLC | $11.85 | 2021 | |
| Allergan, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.